A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma

Array BioPharma

Status and phase: Completed; Phase 1

Conditions: Multiple Myeloma, Plasma Cell Leukemia

Treatments: Drug: Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous; Drug: Bortezomib, proteasome inhibitor; intravenous or subcutaneous; Drug: ARRY-520, KSP(Eg5) inhibitor; intravenous; Drug: Dexamethasone, steroid; oral

Study type: Interventional

Funder types: Industry

Identifiers

NCT01248923

ARRAY-520-111

Details and patient eligibility

About

This is a Phase 1 study during which patients with relapsed or refractory multiple myeloma (MM) or plasma cell leukemia (PCL) will receive investigational study drug ARRY-520 and bortezomib, with or without dexamethasone, with granulocyte-colony stimulating factor (G-CSF) support.

This study has 2 parts. In the first part, patients will receive increasing doses of study drug (2 dosing schedules will be evaluated) in combination with (1) bortezomib with G-CSF support or (2) bortezomib and dexamethasone with G-CSF support, in order to achieve the highest dose of study drug possible that will not cause unacceptable side effects. Approximately 45 patients from the US will be enrolled in Part 1 (Active, not recruiting).

In the second part of this study, patients will receive the best dose(s) and schedule(s) of study drug, in combination with bortezomib ± dexamethasone + G-CSF, determined from the first part of the study and will be followed to see what side effects the combination causes and what effectiveness the combination has, if any, in treating the cancer. Approximately 42 patients from the US will be enrolled in Part 2 (Active, not recruiting).

Enrollment: 55 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Key Inclusion Criteria (Part 1 and Part 2):

• Confirmed relapsed or refractory MM (measurable disease) or PCL.
• Prior treatment regimens for Part 1: Patients should have received at least 2 prior treatment regimens. Prior treatment must have included at least one full cycle of a proteasome inhibitor (e.g., bortezomib or carfilzomib) and at least one full cycle of an IMiD (e.g., thalidomide, lenalidomide or pomalidomide).
• Prior treatment regimens for Part 2: Patients should have received 1 to 3 prior treatment regimens. Prior treatment could have included bortezomib only if the disease was not refractory to treatment with bortezomib (refractory defined as documented progression on therapy or within 60 days of completing treatment with bortezomib).
• The disease should have progressed per IMWG criteria during or after the last prior treatment regimen.
• Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1.
• Adequate hematology laboratory values without transfusion support and without hematological growth factor support within 2 weeks of screening.
• Adequate liver and renal function.
• Additional criteria exist.

Key Exclusion Criteria (Part 1 and Part 2):

• Primary amyloidosis.
• Peripheral neuropathy ≥ Grade 2 or neuropathy with pain, regardless of grade.
• Concomitant malignancies or previous malignancies with less than a 3-year disease free interval at the time of enrollment (patients with adequately resected basal or squamous cell carcinoma of the skin, carcinoma in situ of the cervix or Stage A low grade prostate cancer may enroll irrespective of the time of diagnosis).
• Autologous or allogeneic stem cell or bone marrow transplant within 3 months prior to first dose of study drug.
• Treatment with an investigational medicinal product or device within 28 days prior to first dose of study drug.
• Cytotoxic therapy or monoclonal antibodies within 21 days prior to first dose of study drug.
• Radiotherapy within 21 days prior to first dose of study drug (if the radiation portal covered ≤ 5% of the bone marrow reserve, the patient may be enrolled irrespective of the end date of radiotherapy).
• Major surgery within 14 days and minor surgery within 7 days prior to first dose of study drug.
• Corticosteroid doses > 10 mg/day of prednisone or equivalent within 14 days prior to first dose of study drug.
• Known positive serology for the human immunodeficiency virus (HIV), hepatitis B and/or active hepatitis C.
• Additional criteria exist.

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)

---

55 participants in 3 patient groups

ARRY-520 (Schedule 1) + bortezomib + G-CSF

Experimental group

Treatment:

Drug: Bortezomib, proteasome inhibitor; intravenous or subcutaneous

Drug: Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous

Drug: ARRY-520, KSP(Eg5) inhibitor; intravenous

Drug: Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous

Drug: Bortezomib, proteasome inhibitor; intravenous or subcutaneous

Drug: ARRY-520, KSP(Eg5) inhibitor; intravenous

ARRY-520 (Schedule 1) + bortezomib + dexamethasone + G-CSF

Experimental group

Treatment:

Drug: Bortezomib, proteasome inhibitor; intravenous or subcutaneous

Drug: Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous

Drug: ARRY-520, KSP(Eg5) inhibitor; intravenous

Drug: Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous

Drug: Dexamethasone, steroid; oral

Drug: Bortezomib, proteasome inhibitor; intravenous or subcutaneous

Drug: ARRY-520, KSP(Eg5) inhibitor; intravenous

ARRY-520 (Schedule 2) + bortezomib + dexamethasone + G-CSF

Experimental group

Treatment:

Drug: Bortezomib, proteasome inhibitor; intravenous or subcutaneous

Drug: Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous

Drug: ARRY-520, KSP(Eg5) inhibitor; intravenous

Drug: Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous

Drug: Dexamethasone, steroid; oral

Drug: Bortezomib, proteasome inhibitor; intravenous or subcutaneous

Drug: ARRY-520, KSP(Eg5) inhibitor; intravenous